gila monster saliva glp 1 Weight Loss and monsters. Who knew? Gila monster venom… and weight

Not recommended in case of kidney, heart and cardiovascular disease, neither for people who suffer from diseases accompanied with seizures

(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM

Some individuals may experience gastrointestinal discomfort, such as bloating or cramping

Moreover, the inclusion of L-Arginine in the formula helps to improve overall blood circulation in the body

These defects arise from multiple factors, with periodontitis being the most extensively studied (Sima et al., 2019)

doi: 10.1007/s10534-025-00745-y 39 AslamTAkhtarBSharifAAnjumFAliSFatimaSAet al